ABBV
AbbVieAbbVie is a biotechnology name in the health care sector. Over the past year it returned +15.9%, against +5.1% over three months and +2.1% over one. It trades 15.7% above its 200-day average, so the longer trend is confirming recent strength. Annualized volatility of 25.3% is moderate by single-stock standards.
Its worst peak-to-trough decline over the year was -15.7%, and it has traded a median $1.2B a day, the figure that decides whether a position can actually be entered and exited at posted prices. Its daily moves correlate -0.06 with the S&P 500 proxy, so it has been moving substantially on its own.
How ABBV scores on all four profiles
Its standing on steadiness, defensiveness and rebound, plus the factor-by-factor breakdown behind each score, and its closest and least-correlated peers among 7 others in Biotechnology.
Start a free 7-day trial| 1 day | +1.1% |
| 1 week | -0.2% |
| 1 month | +2.1% |
| 3 months | +5.1% |
| 6 months | +30.6% |
| 1 year | +15.9% |
| 12-1 momentum | +13.5% |
| Volatility (1y, annualized) | 25.3% |
| Max drawdown (1y) | -15.7% |
| Distance vs 200-day average | +15.7% |
| Return per unit of risk | 0.63 |
| Median daily dollar volume | $1.2B |
Get ABBV when it shows up in a ranking
Two editions a weekday, free, ranked lists built from this same data, on whatever the market is talking about.
Everything on this page is computed from daily adjusted closing prices. It contains no earnings, balance-sheet, guidance or ownership data, and it is not a valuation. Nothing here is tailored to your circumstances or a recommendation to buy or sell. Past performance does not predict future results.